SAN DIEGO, May 09, 2011 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it is significantly reducing the price for sequencing whole human genomes through the Illumina Genome Network (IGN). The new list price for the service is $5,000 per genome for projects of ten samples or more, and $4,000 for projects of fifty samples or more. IGN is a global service partnership designed to link researchers interested in conducting large-scale whole human genome sequencing projects with leading institutions that can perform such projects using Illumina sequencers.
"We have been very pleased with the success of IGN since its introduction and with how well it has been received by the community," said Christian Henry, Senior Vice President and General Manager, Life Sciences, at Illumina. "Researchers around the world value the rapid turnaround times, high data quality and accessible price points. Recent advancements in HiSeq technology push that value even further and demonstrate our commitment to continuing to lower cost and drive scale through sequencing technology advancements."
Since its introduction in July 2010, IGN has received orders for more than 1,000 samples from a range of academic and commercial institutions. Illumina's sequencers provide data with the industry's most comprehensive list of variants, the most complete alignment and the fewest gaps. IGN has delivered high-quality data with expert project management to customers across the globe. It is expected that the latest pricing will enable existing and prospective customers to expand their study sizes, increase the depth of sequencing coverage especially for tumor samples, and drive further adoption of whole-genome sequencing as the preferred method for assessing variation across genomes.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the Illumina Genome Network. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Kevin Williams, MD, Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Wilson Grabill, Public Relations
858-882-6822
wgrabill@illumina.com
